[1] Taher A T,Musallam K M,Cappellini M D.β-thalassemias[J]. N Engl J Med,2021,384(8):727-743. [2] Wei D,Cheng Z F,Wei W,et al.Profiling structural variations of the α-globin gene cluster by the single molecule real-time sequencing: remarkable diversity of the spectrum with rare and novel variants identified in a large Chinese cohort[J]. Hum Genet,2026,145(1):9. [3] Lai K T,Huang G F,Su L,et al.The prevalence of thalassemia in mainland China: evidence from epidemiological surveys[J]. Sci Rep,2017,7(1):920. [4] Sankaran V G,Menne T F,Xu J,et al.Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A[J]. Science,2008, 322(5909):1839-1842. [5] Liu N,Hargreaves V V,Zhu Q,et al. Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch[J]. Cell,2018,173(2):430-442.e17. [6] Martyn G E,Wienert B,Yang L,et al.Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding[J]. Nat Genet,2018,50(4): 498-503. [7] Kountouris P,Lederer C W,Fanis P,et al.IthaGenes: an interactive database for haemoglobin variations and epidemiology[J]. PLoS One,2014,9(7):e103020. [8] Farmakis D,Porter J,Taher A,et al.2021 thalassaemia international federation guidelines for the management of transfusion-dependent thalassemia[J]. Hemasphere, 2022,6(8):e732. [9] 中国输血协会免疫血液学专业委员会. 输血依赖型地中海贫血(TDT)患者临床输血中国专家共识[J]. 临床输血与检验,2023,25(2):163-169. [10] Cappellini M D,Viprakasit V,Taher A T,et al.A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia[J]. N Engl J Med,2020,382(13): 1219-1231. [11] Angelucci E,Matthes-Martin S,Baronciani D,et al.Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel[J]. Haematologica,2014,99(5):811-820. [12] Baronciani D, Angelucci E, Potschger U, et al.Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Marrow Transplantation Hemoglobinopathy Registry,2000—2010[J]. Bone Marrow Transplant,2016,51(4):536-541. [13] Liu R R,Xiao H W,Qin C J,et al.A multi-center clinical trial of allogeneic hematopoietic stem cell transplantation in transfusion-dependent thalassemia[J]. Nat Commun,2026,17(1):3083. [14] Locatelli F,Thompson A A,Kwiatkowski J L,et al.Betibeglogene autotemcel gene therapy for non-β0/β0 genotype β-thalassemia[J]. N Engl J Med,2022,386(5): 415-427. [15] Li S,Ling S,Wang D,et al. Modified lentiviral globin gene therapy for pediatric β0/β0 transfusion-dependent β-thalassemia: A single-center,single-arm pilot trial[J]. Cell Stem Cell,2024,31(7):961-973.e8. [16] Cavazzana-Calvo M,Payen E,Negre O,et al.Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia[J]. Nature,2010,467(7313): 318-322. [17] Thompson A A,Walters M C,Kwiatkowski J,et al.Gene therapy in patients with transfusion-dependent beta-thalassemia[J]. N Engl J Med,2018,378(15):1479-1493. [18] Kwiatkowski J L,Walters M C,Hongeng S,et al.Betibeglogene autotemcel gene therapy in patients with transfusion-dependent,severe genotype β-thalassaemia (HGB-212): a non-randomised,multicentre,single-arm, open-label,single-dose,phase 3 trial[J]. Lancet,2024, 404(10468):2175-2186. [19] Kwiatkowski J L,Thompson A A,Schneiderman J,et al.Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia[J]. Blood,2026,147(19):2203-2214. [20] U.S.Food and Drug Administration. ZYNTEGLO (betibeglogene autotemcel) Prescribing Information: FDA Approved Labeling[R]. U.S. Food and Drug Administration, 2022. [21] Bauer D E,Kamran S C,Lessard S,et al.An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level[J]. Science,2013,342(6155):253-257. [22] Canver M C,Smith E C,Sher F,et al.BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis[J]. Nature,2015,527(7577):192-197. [23] Smith E C,Luc S,Croney D M,et al.Strict in vivo specificity of the Bcl11a erythroid enhancer[J]. Blood, 2016,128(19):2338-2342. [24] Frangoul H, Altshuler D, Cappellini M D, et al.CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia[J]. N Engl J Med,2021,384(3):252-260. [25] Fu B,Liao J Y,Chen S H,et al.CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia[J]. Nat Med,2022, 28(8):1573-1580. [26] Locatelli F,Lang P,Wall D,et al.Exagamglogene autotemcel for transfusion-dependent β-thalassemia[J]. N Engl J Med,2024,390(18):1663-1676. [27] Sheth S,Corbacioglu S,de la Fuente J,et al. Correction of ineffective erythropoiesis and normalization of iron homeostasis after exagamglogene autotemcel in transfusion-dependent β-thalassemia[J]. Am J Hematol, 2026,101(8):1969-1979. [28] U.S.Food and Drug Administration. Summary basis for regulatory action: CASGEVY (exagamglogene autotemcel), transfusion-dependent β-thalassemia indication: BLA 125785[R]. Center for Biologics Evaluation and Research (CBER),U.S. Food and Drug Administration, 2024. [29] Yin X L,Qian L X,Dong G Y,et al.Successful gene therapy for transfusion-dependent α-thalassemia: a case report[J]. Blood Adv,2026,10(14):5153-5160. [30] Shaw J,Patra A,Khatun A,et al.Alpha globin gene alterations modifying the phenotype of homozygous beta thalassaemia[J]. EJHaem,2024,5(3):440-446. [31] Case S S,Price M A,Jordan C T,et al.Stable transduction of quiescent CD34+CD38 (-) human hematopoietic cells by HIV-1-based lentiviral vectors[J]. Proc Natl Acad Sci U S A,1999,96(6):2988-2993. [32] Negre O,Bartholomae C,Beuzard Y,et al.Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease[J]. Curr Gene Ther,2015,15(1):64-81. [33] Ferrari S,Jacob A,Cesana D,et al. Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells[J]. Cell Stem Cell,2022,29(10):1428-1444.e9. [34] Frangoul H, Hanna R, Walters M C, et al.CRISPR-Cas12a gene editing of HBG1 and HBG2 promoters to treat β-thalassemia[J]. N Engl J Med,2026,394(13):1292-1301. [35] Lai Y R,Liu R R,Wang L J,et al.Clinical application of base editing for treating β-thalassaemia[J]. Nature,2026, 653(8115):923-932. [36] Badat M,Ejaz A,Hua P,et al.Direct correction of haemoglobin E β-thalassaemia using base editors[J]. Nat Commun,2023,14(1):2238. [37] Hardouin G,Antoniou P,Martinucci P,et al.Adenine base editor-mediated correction of the common and severe IVS1-110 (G>A) β-thalassemia mutation[J]. Blood,2023, 141(10):1169-1179. [38] Anzalone A V,Randolph P B,Davis J R,et al.Search-and-replace genome editing without double-strand breaks or donor DNA[J]. Nature,2019,576(7785):149-157. [39] Zhang H K,Zhou Q,Chen H Y,et al.Prime editor 3 mediated beta-thalassemia mutations of the HBB gene in human erythroid progenitor cells[J]. Int J Mol Sci, 2022,23(9):5002. [40] Zhang H K,Sun R L,Fei J,et al.Correction of beta-thalassemia IVS-II-654 mutation in a mouse model using prime editing[J]. Int J Mol Sci,2022,23(11):5948. [41] Chalumeau A,Bou Dames M,Fontana L,et al.A prime editing strategy to rewrite the γ-globin promoters and reactivate fetal hemoglobin for sickle cell disease[J]. Blood,2025,146(22):2641-2655. [42] Hardouin G,Martinucci P,Scaramuzza S,et al. Base editing of β0-thalassemia mutations as a therapeutic strategy for severe β-hemoglobinopathies[J]. Sci Transl Med,2025,17(826):eadt8617. [43] Mayuranathan T,Newby G A,Feng R P,et al.Potent and uniform fetal hemoglobin induction via base editing[J]. Nat Genet,2023,55(7):1210-1220. [44] Wang L J,Xue W,Zhang H X,et al.Eliminating base-editor-induced genome-wide and transcriptome-wide off-target mutations[J]. Nat Cell Biol,2021,23(5):552-563. [45] Han W Y,Qiu H Y,Sun S W,et al. Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs[J]. Cell Stem Cell,2023,30(12):1624-1639.e8. [46] Fiumara M,Ferrari S,Omer-Javed A,et al.Genotoxic effects of base and prime editing in human hematopoietic stem cells[J]. Nat Biotechnol,2024,42(6):877-891. [47] Turchiano G,Andrieux G,Klermund J,et al. Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq[J]. Cell Stem Cell,2021,28(6):1136-1147.e5. [48] Komor A C,Kim Y B,Packer M S,et al.Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage[J]. Nature,2016,533(7603):420-424. [49] Gaudelli N M,Komor A C,Rees H A,et al.Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage[J]. Nature,2017,551(7681):464-471. [50] Zeng J,Wu Y,Ren C,et al.Therapeutic base editing of human hematopoietic stem cells[J]. Nat Med,2020,26(4): 535-541. [51] Antoniou P,Hardouin G,Martinucci P,et al.Base-editing-mediated dissection of a γ-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression[J]. Nat Commun,2022,13(1):6618. [52] Liao J Y,Chen S H,Hsiao S,et al.Therapeutic adenine base editing of human hematopoietic stem cells[J]. Nat Commun,2023,14(1):207. [53] Kosicki M,Tomberg K,Bradley A.Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements[J]. Nat Biotechnol, 2018,36(8):765-771. [54] Cullot G,Boutin J,Toutain J,et al.CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations[J]. Nat Commun,2019,10(1):1136. [55] Boutin J,Rosier J,Cappellen D,et al.CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells[J]. Nat Commun,2021,12(1):4922. [56] Leibowitz M L,Papathanasiou S,Doerfler P A,et al.Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing[J]. Nat Genet,2021,53(6):895-905. [57] Haapaniemi E,Botla S,Persson J,et al.CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response[J]. Nat Med,2018,24(7):927-930. [58] Cancellieri S,Zeng J,Lin L Y,et al.Human genetic diversity alters off-target outcomes of therapeutic gene editing[J]. Nat Genet,2023,55(1):34-43. [59] U.S.Food and Drug Administration. Human gene therapy products incorporating human genome editing: guidance for industry[Z]. 2024. [60] U.S.Food and Drug Administration. Safety assessment of genome editing in human gene therapy products using next-generation sequencing: draft guidance for industry:Docket No. FDA-2026-D-1255[R]. Rockville, MD:U.S. Food and Drug Administration,Center for Biologics Evaluation and Research,2026. [61] Schiroli G,Conti A,Ferrari S,et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response[J]. Cell Stem Cell,2019,24(4):551-565.e8. [62] Ferrari S,Jacob A,Beretta S,et al.Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking[J]. Nat Biotechnol,2020,38(11):1298-1308. [63] Vavassori V,Ferrari S,Beretta S,et al.Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells[J]. Blood,2023,142(9):812-826. [64] U.S.Food and Drug Administration. Chemistry, manufacturing, and control information for human gene therapy investigational new drug applications: guidance for industry:FDA-2020-D-1138[R]. U.S. Food and Drug Administration,2020. [65] U.S.Food and Drug Administration. Long term follow-up after administration of human gene therapy products: guidance for industry[R]. U.S. Department of Health and Human Services,Center for Biologics Evaluation and Research,2020. [66] Kim H,Zenhausern R,Gentry K,et al.Lipid nanoparticle-mediated mRNA delivery to CD34+ cells in Rhesus monkeys[J]. Nat Biotechnol,2025,43(11):1813-1820. [67] Xu S J,Liang D,Wang Q D,et al.In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery[J]. Nat Biomed Eng,2026,10(3):473-489. [68] U.S.Food and Drug Administration. Potency assurance for cellular and gene therapy products: draft guidance for industry[Z]. 2023. [69] U.S.Food and Drug Administration. Leveraging prior knowledge in the development of human gene therapy products incorporating genome editing: draft guidance for industry:Docket No. FDA-2026-D-1257[R]. U.S. Food and Drug Administration,Center for Biologics Evaluation and Research,2026. [70] Zhang Q Q,Li J L,Huang H Y,et al.Multi-centric origins and gene flow shape the diversity of β-thalassemia mutations in Southern East Asia[J]. Nat Commun,2025, 16(1):10220. [71] Tuo Y Y,Li Y,Li Y,et al.Global,regional,and national burden of thalassemia,1990-2021: a systematic analysis for the global burden of disease study 2021[J]. EClinicalMedicine,2024,72:102619. [72] Doxzen K W,Adair J E,Fonseca Bazzo Y M,et al. The translational gap for gene therapies in low- and middle-income countries[J]. Sci Transl Med,2024,16(746): eadn1902. [73] Kansal A R,Reifsnider O S,Brand S B,et al.Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia[J]. J Market Access Heal Policy,2021,9:1922028. [74] Udeze C,Gargano M,Yang H B,et al.Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with transfusion-dependent β -thalassemia in the United States[J]. J Med Econ,2026,29(1):1134-1148. |